We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.33%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.83B
AUM Growth
-$147M
Cap. Flow
+$37.6M
Cap. Flow %
0.48%
Top 10 Hldgs %
76.26%
Holding
100
New
11
Increased
18
Reduced
11
Closed
5

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$125M
2
INSM icon
Insmed
INSM
+$125M
3
ALKS icon
Alkermes
ALKS
+$103M
4
BCYC
Bicycle Therapeutics
BCYC
+$101M
5
ALMS
Alumis Inc
ALMS
+$20.8M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$308M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$55.5M
3
ROIV icon
Roivant Sciences
ROIV
+$50.6M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$38.2M
5
AKRO
Akero Therapeutics
AKRO
+$34.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.1%
2 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADAP
76
DELISTED
Adaptimmune Therapeutics
ADAP
$2.28M 0.03%
2,343,695
-8,443,327
-78% -$9.27M
MRSN
77
DELISTED
Mersana Therapeutics
MRSN
$2.18M 0.03%
43,445
– –
IPSC icon
78
Century Therapeutics
IPSC
$373M
$2.03M 0.03%
797,460
– –
NAMS icon
79
NewAmsterdam Pharma
NAMS
$3.28B
$1.86M 0.02%
96,827
– –
SAGE
80
DELISTED
Sage Therapeutics
SAGE
$1.86M 0.02%
171,026
-236,191
-58% -$3.03M
VTVT icon
81
vTv Therapeutics
VTVT
$125M
$1.72M 0.02%
97,314
– –
CMPX icon
82
Compass Therapeutics
CMPX
$364M
$1.56M 0.02%
1,557,630
– –
TARA icon
83
Protara Therapeutics
TARA
$218M
$1.12M 0.01%
536,832
+337,161
+169% +$986K
JBIO
84
Jade Biosciences
JBIO
$1.22B
$1.04M 0.01%
17,970
-30,045
-63% -$19.9M
PFE icon
85
Pfizer
PFE
$143B
$979K 0.01%
35,000
– –
ACHL
86
DELISTED
Achilles Therapeutics
ACHL
$904K 0.01%
1,108,767
-100,008
-8% -$87.9K
ALGS icon
87
Aligos Therapeutics
ALGS
$26.9M
$727K 0.01%
83,056
– –
PMVP icon
88
PMV Pharmaceuticals
PMVP
$57.1M
$522K 0.01%
322,024
– –
BCRX icon
89
BioCryst Pharmaceuticals
BCRX
$2.47B
$468K 0.01%
75,778
-10,050,398
-99% -$55.5M
ACRV icon
90
Acrivon Therapeutics
ACRV
$62.9M
$307K ﹤0.01%
52,885
– –
FHTX icon
91
Foghorn Therapeutics
FHTX
$290M
$259K ﹤0.01%
45,027
– –
TYRA icon
92
Tyra Biosciences
TYRA
$1.89B
$170K ﹤0.01%
10,607
– –
SRZNW icon
93
Surrozen Inc Warrant
SRZNW
$36.6K
$13.8K ﹤0.01%
833,333
– –
CABA icon
94
Cabaletta Bio
CABA
$442M
– –
-13,331
Closed -$227K
CATX icon
95
Perspective Therapeutics
CATX
$331M
– –
-14,979
Closed -$178K
FDMT icon
96
4D Molecular Therapeutics
FDMT
$510M
– –
-100,000
Closed -$3.19M
MURA
97
DELISTED
Mural Oncology
MURA
– –
-222,503
Closed -$1.09M
ALPN
98
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-81,578
Closed -$3.23M
1 2 3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2024 Portfolio in Review

As of Q2 2024, Baker Bros. Advisors held 100 positions worth $7.83B, down 1.8% from $7.97B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Baker Bros. Advisors's Q2 2024 filing shows 11 new, 18 increased, 11 reduced and 5 closed positions. Its largest new stake was Summit Therapeutics: 23,222,222 shares worth $181M. The largest sale was Incyte, an estimated $308M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2024 buy was Summit Therapeutics: 23,222,222 shares worth $181M.
  • Baker Bros. Advisors added most to Insmed in Q2 2024, an estimated $125M increase.
  • Baker Bros. Advisors's biggest Q2 2024 reduction was Incyte, cutting an estimated $308M.
  • Baker Bros. Advisors fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $3.23M.
  • Baker Bros. Advisors's ten largest holdings make up 76% of its $7.83B portfolio in Q2 2024.
  • Baker Bros. Advisors opened 11 new positions and closed 5 in Q2 2024.
  • Baker Bros. Advisors's portfolio value fell 1.8% quarter-over-quarter to $7.83B.

Based on Baker Bros. Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.